Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity
about
The P42 peptide and Peptide-based therapies for Huntington's diseaseIntrabodies as neuroprotective therapeuticsThe structure of a polyQ-anti-polyQ complex reveals binding according to a linear lattice modelMonoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment.Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.Interaction of huntingtin fragments with brain membranes--clues to early dysfunction in Huntington's disease.An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicityConformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.Fibril polymorphism affects immobilized non-amyloid flanking domains of huntingtin exon1 rather than its polyglutamine coreFormation of morphologically similar globular aggregates from diverse aggregation-prone proteins in mammalian cells.Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.Polyglutamine amyloid core boundaries and flanking domain dynamics in huntingtin fragment fibrils determined by solid-state nuclear magnetic resonance.Polyglutamine fibrillogenesis: the pathway unfoldsA huntingtin peptide inhibits polyQ-huntingtin associated defectsTargeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases.Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.Polyglutamine- and temperature-dependent conformational rigidity in mutant huntingtin revealed by immunoassays and circular dichroism spectroscopyThe Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases.Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease modelIdentification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein.Development of novel therapies for Huntington's disease: hope and challenge.The emerging role of the first 17 amino acids of huntingtin in Huntington's diseaseBifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.Therapeutics development for triplet repeat expansion diseases.Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtinAlzheimer's disease and HIV associated dementia related genes: I. location and function.HTRF analysis of soluble huntingtin in PHAROS PBMCs.Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapyDeveloping intrabodies for the therapeutic suppression of neurodegenerative pathology.Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease.Molecular mechanisms and potential therapeutical targets in Huntington's disease.The role of IκB kinase complex in the neurobiology of Huntington's disease.Polyglutamine misfolding in yeast: toxic and protective aggregation.Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteinsSingle-chain fragment variable passive immunotherapies for neurodegenerative diseases.Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast.Degradation of mutant huntingtin via the ubiquitin/proteasome system is modulated by FE65.
P2860
Q26764930-1B44FB8D-E81D-4C85-A61A-AB4EFD48F5C3Q27003896-2659A9D9-BF04-4927-A045-A05C5D452D78Q27644551-6ADAE065-0ABB-487D-91F2-BB3DA66D9D31Q30490726-471B1F8D-C59E-4A05-A985-0B96806ABCF6Q30493159-EA7D563F-EB66-4FDA-90F2-B883E106C142Q33231356-5A001860-57D1-41C4-9B14-D13343071740Q33317678-839F936C-4F0D-4CF4-B4DB-29FCDD28412EQ33459255-9ABEA584-6594-4C8D-8374-FC6E383735FBQ33580733-E41EBE8D-A6C7-40A5-8D48-D5F483227B34Q33761247-03AD1864-2DAD-4DD0-8D81-661AE4B3DE1FQ33911387-3D7F0C0D-F05F-4854-A7F7-15A7485AFF78Q33914222-F4C52032-DAD8-40A8-8273-377082CEE3EFQ34075502-453F60AF-A4EE-441E-8424-9CBCD757645AQ34117333-B12411B4-124E-4EC5-AC1E-4CA22B4A6F46Q34414446-772A75A2-E5DB-49A9-BE40-ACCF162ED289Q34466014-B196FF1B-01B8-46D1-B5B8-4C8476E0576AQ34828144-028ABDC0-81DD-4F74-9ED3-91F82F71E03FQ35095142-FBD4B149-9A50-40A9-B685-BD597D05C6FBQ35244160-484E39C4-3FF7-4295-9493-10A102E8A358Q35479250-D662A6F7-D5BA-43C1-9B0E-F66C70D91A47Q35708355-4BB533D2-A635-4619-9DDF-0EBF085E50FEQ35748307-59C38A43-95F2-4CD7-A921-5D084B892719Q35939753-D551A7A9-0D96-474C-B631-A93CF5538248Q36016932-9597886F-250F-4028-A6E6-F4E882095061Q36110838-361EA408-7521-4877-B398-5C4D962170B4Q36185625-E11595A3-FFAA-4E2C-9B83-96069DC07644Q36277195-DF1DFAB6-8DE7-42B4-A490-64229D406590Q36677547-83C7DD71-1464-4335-8E50-4E5321D8B02EQ36782581-50D19BCB-DF45-456E-A867-48E191A9E039Q37227046-DAE8F93B-73AC-4534-AD76-A71E4C9F661BQ37280507-DF637ED2-C50A-4EA7-9EED-ED9FD43A67EEQ37571975-1F5E5E6B-2D48-48D5-9B5C-DC6767DCC2D1Q37607467-232AF19B-814E-453B-9648-127BEB285EA9Q37776087-18B9DF7B-A8FC-4198-ADF1-CDB3E017B8EDQ37873608-DAA2C097-988A-4B93-B450-A10239FFE220Q37952579-ABAE03E9-9566-49DD-8E87-C9049CA1FA2EQ37961564-5E1E5E42-491C-467F-9D8B-0A857FC6822BQ38139218-59A35636-4AFA-40B0-9F8E-9EC40CDAE3C0Q38309637-A90DD31D-1556-4344-9D0F-F63BB3E4D8CDQ38327548-4C624DB8-A8F9-49BF-B781-8650E3F3BFFE
P2860
Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Effects of intracellular expre ...... ngtin aggregation and toxicity
@ast
Effects of intracellular expre ...... ngtin aggregation and toxicity
@en
type
label
Effects of intracellular expre ...... ngtin aggregation and toxicity
@ast
Effects of intracellular expre ...... ngtin aggregation and toxicity
@en
prefLabel
Effects of intracellular expre ...... ngtin aggregation and toxicity
@ast
Effects of intracellular expre ...... ngtin aggregation and toxicity
@en
P2093
P2860
P356
P1476
Effects of intracellular expre ...... ngtin aggregation and toxicity
@en
P2093
Ali Khoshnan
Paul H Patterson
P2860
P304
P356
10.1073/PNAS.022631799
P407
P577
2002-01-15T00:00:00Z